US-based biotechnology company Morphic Therapeutic closed a $51.5m series A round yesterday co-led by SR One and Pfizer Venture Investments, the respective corporate venturing units of pharmaceutical firms GlaxoSmithKline and Pfizer.
AbbVie Ventures, the investment arm of biopharmaceutical firm AbbVie; ShangPharma Investment Group, the corporate venturing vehicle of pharmaceutical holding firm ShangPharma; and chemical simulation software producer Schrödinger also supplied cash.
The corporates were joined by investment firm Omega Funds, VC firm Polaris Partners and company founder Timothy Springer. Schrödinger,…